Skip to main content
NIH funding notice PAR-20-309

Alzheimer's Clinical Trials Consortium (ACTC) Clinical Trials (R01 Clinical Trial Required)

Closed on May 7, 2024.

Posted
November 24, 2020
Close date
May 7, 2024
Activity codes
Not stated on the notice page
Institutes taking part
Not stated on the notice page

Read the notice on Grants.gov · NIH Guide page

The notices it replaced

Its page was not saved, so the notices it replaced are not known.

Who won it before

1 competing award (new and renewals) from FY2014 to FY2025 under this notice and the notices it replaced: $30,887,229 in first-year total cost, median $30,887,229.

Most frequent study sections

  1. Special Emphasis Panel[ZRG1 AN-T (02)]1

Most frequent institutions

  1. UNIVERSITY OF CALIFORNIA, SAN FRANCISCO1
Competing awards under PAR-20-309 and the notices it replaced
FYProjectPIsInstitutionFirst-year costStudy section
2023The Alzheimer's Disease Tau Platform Clinical Trial1R01AG078457-01A1BOXER, ADAM L.JOHNSON, KEITH A.UNIVERSITY OF CALIFORNIA, SAN FRANCISCO, CA$30,887,229ZRG1

Data: Grants.gov's daily extract and NIH's notice pages and award files, in ScienceGraph release conductgrants-2026-11-09-0.1.0. An award is listed only where NIH's own record names the notice, and a PI only by NIH's profile ID. Grants.gov and NIH do not endorse ScienceDex.

ScienceDex for faculty

Your academic CV and NIH biosketch

Make your CV in your school's format and your NIH biosketch from it, then download both as Word files.